Amgen Inc. (AMGN) $282.957.53(2.73%) Bid: 281.01 x 100Ask: 282.94 x 100 January 27, 2025 4:00 PMESTVolume: 3,493,163 After Hours: $282.50-0.45(-0.16%)January 27, 2025 7:06 PMESTVolume: 284,059 USDNasdaq Global SelectDelayed PriceMarket Closed Earnings High Target Price 405.00 Mean...
Amgen (AMGN) Rises Yet Lags Behind Market: Some Facts Worth Knowing Jan. 17, 2025 at 5:50 p.m. ETon Zacks.com Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations Jan. 17, 2025 at 12:15 p.m. ETon Benzinga.com ...
1/244/247/2410/241/251/26$181$237$293$349$405Closing price on 01/16/25: $269.43High$405.00Average$314.91Low$195.00 Current Consensus isHold The current consensus among 27 investment analysts is to hold stock in Amgen. This rating has held steady since September 2024, when it changed from ...
Amgen Inc. price and volume Combination chart with 2 data series. Chart represents Amgen Inc. price and volume over 1Y period The chart has 2 X axes displaying Time, and Time. The chart has 2 Y axes displaying symbol price, and symbol volume.. Feb 2025Dec 2024Oct 2024Aug 2024Jun 2024...
Get Amgen Inc (AMGN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.
Get real-time Amgen (AMGN) stock price quotes, analyst insights, forecasts, news, and information you need to help your stock trading and investing.
Amgen Inc. is a multinational biotechnology and pharmaceutical company. It produces various drugs, including Neulasta, which prevents infections for patients undergoing cancer chemotherapy, Enbrel, a necrosis blocker for the treatment of autoimmune diseases. Focusing on molecular biology and biochemistry, Am...
Discover real-time Amgen Inc. Common Stock (AMGN) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.
Amgen Says Lumakras With Vectibix Approved by FDA for Metastatic Colorectal CancerJan. 17MT Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price TalksJan. 17MT Amgen Inc. Announces FDA Approves LUMAKRAS® in Combination with Vectibix® (Panitumumab) for Chemorefractory KRAS G...
04332 AMGEN-T Watchlist 0.000 0.0000.00% Not Open Jan 8 09:30 CST 0Market Cap0.00P/E (TTM) 0.000High0.000Low0Volume0.000Open0.000Pre Close0.00Turnover0.00%Turnover Ratio0.00P/E (Static)537.53MShares1761.00052wk High0.00P/B0Float Cap1761.00052wk Low--Dividend TTM537.53MShs Float1850.000...